Current best practices and rationalistic perspectives in causation-based prevention, early detection and multidisciplinary treatment of breast and gastric cancer

Gastric & Breast Cancer e-journal
DOI: 10.2122/gbc.2012.0216

REVIEW

Management of advanced non-clear cell renal carcinoma.

Khosravi-Shahi Parham, MD, PhD

Affiliation: Khosravi-Shahi Parham, Chief of Medical Oncology Department, Servicio de Oncología, Hospital de Torrejón, Calle Mateo Inurria, s/n, Torrejón de Ardoz, 28850, Madrid, Spain.

E-mail: drkhosravi@hotmail.com

Summary
Renal cell carcinoma (RCC) comprises 2-3% of all malignancies. Approximately 90% of renal tumors are RCCs, and 15% of these are non-clear cell tumors, which include papillary, chromophobe, Bellini duct (collecting duct) and sarcomatoid tumors. Antiangiogenic agents (sorafenib, sunitinib, pazopanib, temsirolimus, or bevacizumab), have not been specifically evaluated in phase III trials in patients with non-clear cell tumors. Therefore, their efficacy is unclear in the treatment of non-clear cell renal carcinomas. In a subset analysis of a randomized phase III trial, patients with non-clear cell and clear cell advanced RCCs, treated with temsirolimus, demonstrated comparable median overall and progression-free survival. In addition, temsirolimus resulted in a superior clinical benefit rate compared with interferon-alfa, regardless of tumor histology. Patients with metastatic papillary and chromophobe RCCs may have prolonged progression-free survival from sunitinib and sorafenib, although clinical responses remain overall low. Therefore, although there are some evidences supporting the use of these agents in patients with non-clear cell RCCs, additional prospective trials with these agents are needed to further clarify their use in these histologic subtypes. This review article focuses on all these options for non-clear cell advanced RCC.

(Citation: Gastric & Breast Cancer 2012; 11(2) 94-101).

Back

 

You can have an online full-text access and a PDF of this article:
  • Either purchase this paper for €35 EUR. Please, click here
Please specify DOI of article
  • Or through one year subscription PayPal

Online ISSN : 1109 - 7647
   Print ISSN : 1109 - 7655

We subscribe to the HONcode principles of the HON Foundation. Click to verify. We subscribe to the HONcode principles. Verify here.
please, read our policy about privacy and confidentiality of information and transparency of sponsorship

last update: 17 March 2012